RSS-Feed abonnieren
DOI: 10.1055/s-2003-38829
Prediction, Prevention, and Treatment of Venous Thromboembolic Disease in Pregnancy
Publikationsverlauf
Publikationsdatum:
23. April 2003 (online)
ABSTRACT
Pregnancy is recognized as an independent risk factor for venous thromboembolism leading to thromboembolic events, particularly in women with prior venous thrombosis, family history of thrombosis, or additional thrombophilic risk factors. To reduce the incidence of venous thromboembolism in pregnancy and improve outcomes, an individual risk stratification on the basis of probability of thrombosis as a rationale for an individual risk-adapted prophylaxis is required. In women without prior thrombosis, the presence of a heterozygous factor V Leiden or heterozygous G20210A mutation in the prothrombin gene is associated with a pregnancy-associated thrombotic risk of approximately 1 in 400. Thus, in pregnant carriers of either one of these mutations the risk of venous thromboembolism is low. For this reason, routine thrombophilia screening of all pregnant women is not recommended. However, a combination of the two genetic risk factors can increase the risk to a modest level (risk 1 in 25). In women with a single episode of prior thrombosis associated with a transient risk factor (such as surgery or trauma) and no additional genetic risk factor, the probability of a pregnancy-associated thrombosis also appears to be low. In contrast, in women with a prior idiopathic venous thrombosis who carry an additional hereditary risk factor or who have a positive family history of thrombosis, a high risk (> 10%) can be expected, supporting the indication for active antepartum and postpartum heparin prophylaxis. In many cases, the absolute magnitude of risk is unknown or estimated, and recommendations are often empiric.
KEYWORDS
Pregnancy - venous thrombosis - risk factors - therapy - prevention
REFERENCES
- 1 National Institutes of Health Consensus Development Conference. Prevention of venous thrombosis and pulmonary embolism. JAMA . 1986; 256 744-749
- 2 Kierkegaard A. Incidence and diagnosis of deep vein thrombosis associated with pregnancy. Acta Obstet Gynaecol Scand . 1983; 62 239-243
- 3 Treffers P E, Huidekoper B L, Weenink G, Kloosterman G. Epidemiological observations of thromboembolic disease during pregnancy and in the puerperium, in 56,022 women. Int J Gynaecol Obstet . 1983; 21 327-331
- 4 Rutherford S, Montoro M, Mc Gehee W, Strong T. Thromboembolic disease associated with pregnancy: an 11-year review (Abst). Am J Obstet Gynecol . 1991; 164(Suppl) 186
- 5 Greer I A. Epidemiology, risk factors and prophylaxis of venous thromboembolism in obstetrics and gynaecology. Clin Obstet Gynaecol . 1997; 11 403-430
- 6 Greer I A. Thrombosis in pregnancy: maternal and fetal issues. Lancet . 1999; 353 1258-1265
- 7 Mc Coll M, Walker I, Greer I A. The role of inherited thrombophilia in venous thromboembolism associated with pregnancy. Br J Obstet Gynaecol . 1999; 106 756-766
- 8 Greer I A. The challenge of thrombophilia in maternal-fetal medicine. N Engl J Med . 2000; 342 424-425
- 9 Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med . 2001; 344 1222-1231
- 10 Rosendaal F R. Venous thrombosis: a multicausal disease. Lancet . 1999; 353 1453-1457
- 11 Mansvelt E PG, Laffan M, McVey J H, Tuddenham E GD. Analysis of the F8 gene in individuals with high plasma factor VIII:C levels and associated venous thrombosis. Thromb Haemost . 1998; 80 561-565
- 12 Virchow R. Phlogose und Thrombose im Gefäßsystem. In: Gesammelte Abhandlungen zur Wissenschaftlichen Medizin Frankfurt: Staatsdruckerei; 1856
- 13 Greer I A. Haemostasis and thrombosis in pregnancy. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and Thrombosis London: Churchill Livingstone 1994: 987-1015
- 14 Walker I D. Thrombophilia in pregnancy. J Clin Pathol . 2000; 53 573-580
- 15 Macklon N S, Greer I A, Bowman A W. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br J Obstet Gynaecol . 1997; 104 191-197
- 16 Ginsberg J S, Brill-Edwards P, Burrows R F. et al . DVT during pregnancy: leg and trimester of presentation. Thromb Haemost . 1992; 67 519-520
- 17 Cockett F B, Thomas M L, Negus D. Iliac vein compression: its relation to iliofemoral thrombosis and the post-thrombotic syndrome. BMJ . 1967; 2 214-219
- 18 Ginsberg J S, Greer I A, Hirsh J. Use of antithrombotic agents during pregnancy. Chest . 2001; 119 122S-131S
- 19 Conard J, Horellou M H, van Dreden P, le Compte T, Samama M. Thrombosis in pregnancy and congenital deficiencies in ATIII, protein C or protein S: study of 78 women. Thromb Haemost . 1990; 63 319-320
- 20 De Stefano V, Leone G, Mastrangelo S. et al . Thrombosis during pregnancy and surgery in patients with congenital deficiency of antithrombin, protein C, protein S (Letter). Thromb Haemost . 1994; 71 799-800
- 21 Pabinger I, Schneider B, and the Study Group on Natural Inhibitors. Thrombotic risk in hereditary antithrombin, protein C or protein S deficiency. Arterioscl Thromb Vasc Biol . 1996; 16 742-748
- 22 Friederich P, Sanson B J, Simioni P. et al . Frequency of pregnancy related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med . 1996; 125 955-960
- 23 Gerhardt A, Scharf R E, Beckmann M W. et al . Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med . 2000; 342 374-380
- 24 Dahlbäck B, Carlsson M, Svensson P J. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C. Proc Natl Acad Sci USA . 1993; 90 1004-1008
- 25 Bertina R M, Koeleman P C, Köster T. et al . Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature . 1994; 369 64-66
- 26 Rees D C, Cox M, Clegg J B. World distribution of factor V Leiden. Lancet . 1995; 346 1133-1134
- 27 Köster T, Rosendaal F R, Briet E. et al . Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood . 1995; 85 2756-2761
- 28 van den Belt G M A, Prins M H, Huisman M H, Hirsh J. Familial thrombophilia: a review analysis. Clin Appl Thromb Hemost . 1996; 2 227-236
- 29 Rosendaal F R, Köster T, Vandenbroucke J P, Reitsma P H. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood . 1995; 85 1504-1508
- 30 Emmerich J, Rosendaal F R, Cattaneo M. et al . Combined effect of factor V Leiden and Prothrombin 20210A on the risk of venous thromboembolism. Thromb Haemost . 2001; 86 809-816
- 31 Hellgren M, Svensson P J, Dahlbäck B. Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol . 1995; 173 210-213
- 32 Hallak M, Senderowicz J, Cassel A. et al . Activated protein C resistance (factor V Leiden) associated with thrombosis in pregnancy. Am J Obstet Gynecol . 1997; 176 889-893
- 33 Bokarewa M I, Bremme K, Blombäck M. Arg506-Gln mutation in factor V and risk of thrombosis during pregnancy. Br J Haematol . 1996; 92 473-478
- 34 Mc Coll D M, Ramsey J E, Tait R C. et al . Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost . 1997; 78 1183-1188
- 35 Grandone E, Margaglione M, Colaizzo D. et al . Genetic susceptibility to pregnancy-related venous thromboembolism: roles of factor V- Leiden, prothrombin G20210A, and methylenetetrahydrofolate reductase C677T mutations. Am J Obstet Gynecol . 1998; 179 1324-1328
- 36 McColl M D, Ellison J, Reid F. et al . Prothrombin 20210G-A, MTHFR C677T mutations in women with venous thromboembolism associated with pregnancy. Br J Obstet Gynaecol . 2000; 107 565-569
- 37 Poort S R, Rosendaal F R, Reitsma P H, Bertina R M. A common genetic variation in the &3acute; untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and increase in venous thrombosis. Blood . 1996; 88 3698-3703
- 38 Rosendaal F R, Doggen C JM, Zivelin A. et al . Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost . 1998; 79 706-708
- 39 Martinelli I, Sacchi E, Landi G. et al . High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med . 1998; 338 1793-1797
- 40 Ghavari A E, Pierangeli S S. Origin of antiphospholipid antibodies: induction of aPL by viral peptides. Lupus . 1998; 7 52-54
- 41 Ghavari A E, Sammaritano L R, Wen J. et al . Characteristics of human immunodeficiency virus and chlorpromazine induced antiphospholipid antibodies: effect of beta 2 glycoprotein I on binding to phospholipid. J Rheumatol . 1994; 21 94-99
- 42 Love P E, Santoro S A. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematodes (SLE) and non SLE disorders. Ann Intern Med . 1990; 112 682-698
- 43 Long A A, Ginsberg J S, Brill-Edwards P. et al . The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematodes: a cross sectional study. Thromb Haemost . 1991; 66 520-524
- 44 Ginsberg J S, Brill-Edwards P, Johnston M. et al . Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematodes: a cross sectional study. Blood . 1992; 80 975-980
- 45 Levine J S, Branch D W, Rauch J. The antiphospholipid syndrome. N Engl J Med . 2002; 346 752-763
- 46 Ginsberg J S, Wells P S, Brill-Edwards P. et al . Antiphospholipid antibodies and venous thromboembolism. Blood . 1995; 86 3685-3691
- 47 Simioni P, Prandoni P, Zanon E. et al . Deep venous thrombosis and lupus anticoagulant. Thromb Haemost . 1996; 76 187-189
- 48 Mateo J, Oliver A, Borrell M, Sala N, Fontcuberta J. Laboratory evaluation and clinical characterisation of 2132 consecutive unselected patients with venous thromboembolism-results of the Spanish multicentre study on thrombophilia (EMET-study). Thromb Haemost . 1997; 77 444-451
- 49 Kamashta M A, Cuadrado M J, Mujic F. et al . The management of thrombosis in the antiphospholipid syndrome. N Engl J Med . 1995; 332 993-997
- 50 Brill-Edwards P, Ginsberg J S, Gent M. et al . Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Engl J Med . 2000; 343 1439-1444
- 51 Zotz R B, Gerhardt A, Scharf R E. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium (Letter). N Engl J Med . 2000; 342 1996-1997
- 52 Flessa H C, Klapstrom A B, Glueck M J, Will J J. Placental transport of heparin. Am J Obstet Gynecol . 1965; 93 570-573
- 53 Blombäck M, Bremme K, Hellgren M, Lindberg H. A pharmacokinetic study of dalteparin during late pregnancy. Blood Coagul Fibrinolysis . 1998; 9 343-350
- 54 Forestier F, Daffos F, Capella-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy: study by direct fetal blood sampling under ultrasound. Thromb Res . 1984; 34 557-560
- 55 O'Reilly R. Anticoagulant, antithrombotic and thrombolytic drugs. In: Gillmann AG, Goodman LS, eds. The Pharmacologic Basis of Therapeutics, 6th ed New York: Macmillan 1980: 1347
- 56 Warkentin T E, Levine M N, Hirsh J. et al . Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med . 1995; 332 1330-1335
- 57 Sanson B J, Lensing A WA, Prins H M. et al . Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost . 1999; 81 668-672
- 58 Douketis J D, Ginsberg J S, Burrows R F. et al . The effects of long-term heparin therapy during pregnancy on bone density. A prospective matched cohort study. Thromb Haemost . 1996; 75 254-257
- 59 Pettilä V, Kaaja R, Leinonen P. et al . Thromboprophylaxis with low molecular weight heparin (dalteparin) in pregnancy. Thromb Res . 1999; 96 275-282
- 60 Bates S M, Ginsberg J S. Anticoagulants in pregnancy: fetal defects. In: Greer IA, ed. Bailliere's Clinical Obstetrics and Gynaecology-Thromboembolic Disease in Obstetrics and Gynaecology London: Bailliere Tindall 1997: 479-488
- 61 Elkayam U. Pregnancy through a prosthetic heart valve. J Am Coll Cardiol . 1999; 33 1642-1645
- 62 Chan W S, Anand S, Ginsberg J S. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med . 2000; 160 191-196
- 63 Tait R C, Walker I D, Perry D J. et al . Prevalence of antithrombin deficiency in the healthy population. Br J Haematol . 1994; 87 106-112
- 64 Tait R C, Walker I D, Reitsma P H. et al . Prevalence of protein C deficiency in the healthy population. Thromb Haemost . 1995; 73 87-93